Observational Study of HA380 Blood Perfusion Adsorption Combined with Continuous Renal Replacement Therapy in the Treatment of Sepsis
Description
Methods: Forty septic patients who underwent CRRT in our hospital from February 1, 2023 to December 31, 2023 were selected as the study subjects. Based on the sequential admission numbers of the patients, they were randomly divided into a treatment group (TM group) and a control group (Ctrl group), with 20 patients in each group. Both groups of patients received standard treatment and continuous veno-venous hemofiltration (CVVH) until hemodynamic stability was achieved. On this basis, the TM group was accompanied with HA380 BPA therapy, administered at least once within 24 hours of admission, with each perfusion lasting 4 hours, once a day, for a total of 3 times. Statistical analysis was conducted to assess changes in clinical indicators before and after treatment in two patient groups, including rates of adverse events, bleeding events, and the 28-day mortality rate.